慢性疼痛中使用大麻素化合物的指南。
Guidelines for the use of cannabinoid compounds in chronic pain.
机构信息
University of Calgary, Calgary, Alberta.
出版信息
Pain Res Manag. 2005 Autumn;10 Suppl A:44A-6A. doi: 10.1155/2005/894781.
OBJECTIVE
To provide clinicians with guidelines for the use of cannabinoid compounds in the treatment of chronic pain.
METHODS
Publications indexed from 1990 to 2005 in the National Library of Medicine Index Medicus were searched through PubMed. A consensus concerning these guidelines was achieved by the authors through review and discussion.
RESULTS
There are few clinical trials, case reports or case series concerning the use of cannabinoid compounds in the treatment of chronic pain. There are no randomized clinical trials examining the use of herbal cannabis in the treatment of chronic pain.
CONCLUSIONS
A practical approach to the treatment of chronic pain with cannabinoid compounds is presented. Specific suggestions about the off-label dosing of nabilone (Cesamet, Valeant Canada limitee/Limited) and dronabinol (Marinol, Solvay Pharma Inc, Canada) in the treatment of chronic pain are provided.
目的
为临床医生提供使用大麻素化合物治疗慢性疼痛的指南。
方法
通过 PubMed 检索了 1990 年至 2005 年在国家医学图书馆医学索引中索引的出版物。作者通过审查和讨论就这些指南达成了共识。
结果
关于大麻素化合物治疗慢性疼痛的临床试验、病例报告或病例系列很少。没有随机临床试验研究药用大麻治疗慢性疼痛的作用。
结论
提出了一种用大麻素化合物治疗慢性疼痛的实用方法。提供了关于使用大麻素化合物治疗慢性疼痛时纳布啡（Cesamet，Valeant Canada limitee/Limited）和大麻隆（Marinol，Solvay Pharma Inc，加拿大）的标签外剂量的具体建议。
Zotero 插件